Adjuvant Development Program

Country:

United States

Notice/Contract Number:

fbo:baa-nih-niaid-dait-08-11 hhsn272200800039c

Publication Date:

Oct 5, 2008

Funding Agency:

Department of Health and Human Services

Buyer:

National Institutes of Health

Original Language:

English

Address:

United States

Email:

Click here

73100000 - Research and experimental development services

The purpose of this solicitation is to establish a new Adjuvant Development Program to advance a novel class of vaccine adjuvants towards licensure for human use. This novel class of adjuvants stimulates the innate immune response and demonstrates strong adjuvant properties in animal models. These candidate vaccine adjuvants will be developed for human use with currently licensed or new investigational vaccine immunogens, to protect against NIAID Category A, B, or C Priority Pathogens. This initiative supports the development of candidate vaccine adjuvants through immunological characterization studies, lead compound optimization, and/or Investigational New Drug (IND)-enabling studies, for a period not to exceed five (5) years. Work must include studies on at least one Category A, B, or C Priority Pathogen. Additional studies may be focused on other human infectious pathogens with sufficient justification of an ultimate application to Biodefense. Studies with HIV will not be supported.
Awardee: Vaxine PTY, Inc., 401 Clunies Ross Street , Canberra, 1 ACT 2601 AU
Awarded $8,394,390 on 2008/09/30
Contact: Thomas P Hastings-Tickerhoff , Contracting Officer, Phone 301-496-0194, Fax 301-480-4675, Email ph23k@nih.gov - Thomas P Hastings-Tickerhoff , Contracting Officer, Phone 301-496-0194, Fax 301-480-4675, Email ph23k@nih.gov

Link To Document

Adjuvant Development Program

Contract Award

General Information

Contact Information

Goods, Works and Services

Original Text

dgMarket - Tenders and consulting opportunities worldwide